Cell surface expression of the SC5 mAb domain of vimentin was observed for cutaneous T-cell lymphomas [8] and earlier the CLNH11.4 MAb was shown to detect vimentin on the surface of a variety of malignant cells including prostate cancer cells, but not on healthy cells [9-11]. This evidence concerns the gene VIM and primary cutaneous T-cell non-Hodgkin lymphoma.